Expanding Diagnostic Capabilities
GE HealthCare is reportedly in advanced talks to acquire Sofie Biosciences for $1 billion.
Anonymous
Key Points
1
Sofie’s most advanced pipeline consists of FAPI tracers, with two Phase 3 trials testing their ability to detect metastatic gastroesophageal and pancreatic cancers; the first gastroesophageal-trial patient was dosed in late December 2025.
2
Sofie has built a U.S. network of about 15 radiopharmacies that produces more than 567,000 doses annually, highlighting that the company’s value includes a distributed manufacturing and delivery infrastructure as well as drug candidates.
3
GE HealthCare and Sofie were already commercial partners: under an October 2023 exclusive licensing agreement, GE received worldwide rights to FAPI-46 and rights outside the United States to FAPI-74, while Sofie retained U.S. clinical rights to FAPI-74.
4
Sofie is largely owned by its founders and management, while private-equity firm Trilantic acquired a 25.8% stake in 2024 in a transaction that valued the company at as much as $550 million.
5
The proposed deal could be announced as soon as the following week if negotiations remain on track, although the parties had not finalized an agreement.
GE HealthCare is in advanced talks to acquire Sofie Biosciences for approximately $1 billion, Radiology Business reported. The deal would bolster GE HealthCare's radiopharmaceutical diagnostics arm by adding Sofie's cancer-imaging drugs and a nationwide network of 15 radiopharmacies that produce over 567,000 doses annually.
Sofie develops radioactive tracers used in PET scans for detecting cancers. The company's lead compounds, called FAPI tracers, are in Phase 3 trials for metastatic gastroesophageal and pancreatic cancers. An announcement could come as soon as the following week if negotiations stay on track, Radiology Business noted.
Sofie's Cancer-Imaging Pipeline and Manufacturing Footprint
Sofie's most advanced program centers on FAPI tracers—compounds that light up tumors in medical imaging. Two Phase 3 trials are testing whether these tracers can detect metastatic cancers in the gastrointestinal system and pancreas, Pulse2 reported. The first gastroesophageal trial dosed its initial patient in late December 2025.
Beyond drug candidates, Sofie operates a U.S. network of radiopharmacies capable of producing and delivering short-lived isotopes—compounds that decay rapidly—to hospitals. The company produces more than 567,000 doses annually from its 15-pharmacy network, giving any acquirer immediate recurring revenue from consumables rather than one-time equipment sales.
GE HealthCare's Existing Partnership With Sofie
GE HealthCare and Sofie are already commercial partners. Under an October 2023 agreement, GE received worldwide rights to FAPI-46 and rights outside the United States to FAPI-74. Sofie kept U.S. clinical rights to FAPI-74, allowing both companies to co-develop the technology. The acquisition would deepen that relationship and consolidate control.
Sofie's Ownership Structure and Recent Valuation
Sofie is largely owned by its founders and management team. Private-equity firm Trilantic acquired a 25.8% stake in 2024 in a transaction that valued the company at as much as $550 million. The proposed $1 billion deal represents an 82% premium to that earlier valuation, reflecting investor appetite for radiopharmaceutical assets and manufacturing infrastructure.
GE HealthCare's Strategy in Diagnostic Imaging
The deal would mark GE HealthCare's second major acquisition since spinning off from General Electric. Acquiring Sofie would blend recurring consumable sales—the radiopharmaceutical doses—with GE's existing medical-imaging equipment business, creating a more stable revenue model. Benzinga noted the transaction would expand GE's pharmaceutical diagnostics footprint and position it for future growth in radioligand therapies.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
82
Reach
95
A
AnonymousAuthor
